Article
JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms.
British journal of haematology - 1 Jun 2015
Parampalli Yajnanarayana Sowmya, Stübig Thomas, Cornez Isabelle, Alchalby Haefaa, Schönberg Kathrin, Rudolph Janna, Triviai Ioanna, Wolschke Christine, Heine Annkristin, Brossart Peter, Kröger Nicolaus, Wolf Dominik
Abstract excerpt
Ruxolitinib (INCB018424) is the first JAK1/JAK2 inhibitor approved for treatment of myelofibrosis. JAK/STAT-signalling is known to be involved in the regulation of CD4(+) T cells, which critically orchestrate inflammatory responses. To better understand how ruxolitinib modulates CD4(+) T cell responses, we undertook an in-depth analysis of CD4(+) T cell function upon ruxolitinib exposure. We observed a decrease...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.